Lupin delays VISUfarma close date, doubles down on India obesity-drug push
Lupin said its acquisition of Dutch eye-care firm VISUfarma is now expected to close by Feb. 28, 2026, later than its previous end-2025 target. The company also signed an exclusive India licensing and supply deal with China’s Gan & Lee for the diabetes and weight-loss injection bofanglutide.
